Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.9K
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

18.8K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
18.8K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

31
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
31
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

18.7K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Genome Annotation and Assembly03:36

Genome Annotation and Assembly

21.2K
The genome refers to all of the genetic material in an organism. It can range from a few million base pairs in microbial cells to several billion base pairs in many eukaryotic organisms. Genome assembly refers to the process of taking the DNA sequencing data and putting it all back together in a correct order to create a close representation of the original genome. This is followed by the identification of functional elements on the newly assembled genome, a process called genome annotation.
21.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource.

Nature·2026
Same author

Population-scale repeat expansions elucidate disease risk and brain atrophy.

Nature·2026
Same author

Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes.

Nature·2026
Same author

Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Nature genetics·2026
Same author

Disrupted O-GalNAc glycosylation as a mechanism and biomarker of <i>SLC35A2</i>-associated epilepsy.

bioRxiv : the preprint server for biology·2026
Same author

Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant.

JAMA network open·2026

Related Experiment Video

Updated: Feb 25, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K

Annotating pathogenic non-coding variants in genic regions.

Sahar Gelfman1,2, Quanli Wang3,4, K Melodi McSweeney3,4

  • 1Institute for Genomic Medicine, Columbia University Medical Center, New York, New York, 10032, USA. sahar.gelfman@columbia.edu.

Nature Communications
|August 11, 2017
PubMed
Summary
This summary is machine-generated.

The Transcript-inferred Pathogenicity (TraP) score accurately identifies disease-causing non-coding genetic variants, including synonymous and intronic types. This novel tool aids in gene discovery and personal genome interpretation by pinpointing rare, pathogenic variants.

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.6K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.9K

Related Experiment Videos

Last Updated: Feb 25, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.6K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.9K

Area of Science:

  • Genomics
  • Medical Genetics
  • Bioinformatics

Background:

  • Accurate genetic variant interpretation is crucial for understanding disease.
  • Current methods often miss pathogenic non-coding variants, specifically synonymous and intronic types, hindering disease risk assessment.

Purpose of the Study:

  • To introduce the Transcript-inferred Pathogenicity (TraP) score for reliably identifying pathogenic non-coding genetic variants.
  • To develop a tool that overcomes limitations of existing methods in detecting disease-associated synonymous and intronic variants.

Main Methods:

  • Development of the TraP score utilizing sequence context alterations to predict variant pathogenicity.
  • Validation of TraP using public datasets of synonymous and intronic variants, assessing performance via AUC.
  • Application of TraP to exome data from epilepsy family trios to identify disease-associated variants.

Main Results:

  • TraP accurately distinguishes pathogenic from benign synonymous (AUC=0.88) and intronic (AUC=0.83) variants with high specificity.
  • The score identifies extremely rare variants with lower minor allele frequencies compared to missense variants.
  • Analysis of epilepsy trios revealed pathogenic synonymous variants in known epilepsy genes using TraP.

Conclusions:

  • The TraP score is a valuable tool for identifying pathogenic non-coding variants, improving gene discovery and personal genome interpretation.
  • TraP outperforms existing methods in detecting pathogenic non-coding variants, offering a significant advancement in genetic diagnostics.
  • The availability of a web server with pre-computed scores facilitates broader application of TraP.